NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00009-5091-25 | 00009-5091 | Epirubicin Hydrochloride | Ellence | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Mar 24, 2025 | In Use | |
00480-9257-08 | 00480-9257 | Octreotide Acetate | Octreotide Acetate | 1.667 mg/ml | Hormonal Therapy | Somatostatin Analog | Intramuscular | Mar 20, 2025 | In Use | ||
83831-0120-02 | 83831-0120 | Cyclophosphamide | Frindovyx | 1.0 g/2mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 19, 2025 | In Use | |
60505-6414-01 | 60505-6414 | Melphalan HCl | IVRA | 90.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 19, 2025 | In Use | |
80978-0641-01 | 80978-0641 | Melphalan | IVRA | 90.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 19, 2025 | In Use | |
60505-6435-00 | 60505-6435 | Eribulin mesylate | Eribulin mesylate | 0.5 mg/mL | Chemotherapy | Antimitotic Agent | Furopyrans | Intravenous | Mar 19, 2025 | In Use | |
83831-0121-04 | 83831-0121 | Cyclophosphamide | Frindovyx | 2.0 g/4mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 19, 2025 | In Use | |
83831-0119-01 | 83831-0119 | Cyclophosphamide | Frindovyx | 500.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 19, 2025 | In Use | |
75907-0224-04 | 75907-0224 | Abiraterone Acetate | Abiraterone Acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Mar 17, 2025 | In Use | |
80425-0486-01 | 80425-0486 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 17, 2025 | In Use | |
80425-0491-01 | 80425-0491 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 17, 2025 | In Use | |
80425-0486-02 | 80425-0486 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 17, 2025 | In Use | |
83634-0454-61 | 83634-0454 | Leuprolide acetate | Leuprolide Acetate | 5.0 mg/mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Mar 15, 2025 | In Use | ||
42291-0035-15 | 42291-0035 | Lapatinib | Lapatinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Mar 12, 2025 | In Use | |
72237-0106-01 | 72237-0106 | Selinexor | XPOVIO | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | Mar 10, 2025 | In Use | |
72162-2464-02 | 72162-2464 | Mitomycin | Mitomycin | 5.0 mg/10mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Mar 6, 2025 | In Use | |
70518-3512-07 | 70518-3512 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Mar 6, 2025 | In Use | |
68001-0622-05 | 68001-0622 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 5, 2025 | In Use | |
55154-2146-00 | 55154-2146 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 5, 2025 | In Use | |
71731-4171-01 | 71731-4171 | Eribulin Mesylate | Eribulin Mesylate | 0.5 mg/mL | Chemotherapy | Antimitotic Agent | Furopyrans | Intravenous | Mar 4, 2025 | In Use | |
70518-4302-00 | 70518-4302 | HYDROXYUREA | HYDROXYUREA | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Mar 4, 2025 | In Use | |
61314-0866-02 | 61314-0866 | Pegfilgrastim-bmez | ZIEXTENZO | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Colony-Stimulating Factor | Subcutaneous | Mar 3, 2025 | In Use | |
70771-1904-03 | 70771-1904 | Dasatinib | Dasatinib | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
70771-1902-06 | 70771-1902 | Dasatinib | Dasatinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
70377-0050-12 | 70377-0050 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2025 | In Use |
Found 11561 results — Export these results